CPX
ITRM

Canaan Partners X’s Iterum Therapeutics ITRM Stock Holding History

Canaan Partners X’s Portfolio ITRM Stock Details ITRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-115,545
Closed -$351K – 3
2022
Q2 		$346K Hold
115,545
– – 0.6% 3
2022
Q1 		$615K Hold
115,545
– – 0.62% 4
2021
Q4 		$679K Hold
115,545
– – 0.26% 4
2021
Q3 		$967K Hold
115,545
– – 0.28% 5
2021
Q2 		$4M Hold
115,545
– – 6.01% 3
2021
Q1 		$2.44M Hold
115,545
– – 3.33% 3
2020
Q4 		$1.71M Hold
115,545
– – 3.56% 3
2020
Q3 		$1.82M Hold
115,545
– – 3.62% 3
2020
Q2 		$2.06M Hold
115,545
– – 2.47% 3
2020
Q1 		$4.7M Hold
115,545
– – 5.17% 3
2019
Q4 		$7.8M Buy
+115,545
New +$5.64M 5.04% 3

Other funds holding ITRM

NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
KF
Krilogy Financial St. Louis, Missouri $3.38B AUM 30.57% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
GC
Grimes & Company Westborough, Massachusetts $4.62B AUM 29.71% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Canaan Partners X's ITRM Position: Q3 2022 in Review

Canaan Partners X sold out of Iterum Therapeutics (ITRM) in Q3 2022, closing a stake of 115,545 shares — an estimated $351K sold.

Canaan Partners X first reported a position in ITRM in Q4 2019 and held it in 11 quarters. The position peaked at $7.8M in Q4 2019. 25 funds tracked by Wall St. Rank hold ITRM as of Q3 2022.

  • Canaan Partners X reported no remaining Iterum Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Canaan Partners X sold 115,545 Iterum Therapeutics shares in Q3 2022, an estimated $351K.
  • Canaan Partners X first reported a position in Iterum Therapeutics in Q4 2019 and held it in 11 quarters.
  • Canaan Partners X's Iterum Therapeutics position peaked at $7.8M in Q4 2019.
  • 25 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q3 2022.

Based on Canaan Partners X's 13F filing for Q3 2022, filed 31 Oct 2022.